Company Analysis
Sign in

Crinetics Pharmaceuticals, Inc. (CRNX)

CRNX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.1
◀ Past 3.5● Present 4.2▶ Future 6.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

31 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Crinetics Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
31
31 utility, 1976 to Dec 31, 2025
Granted in 2025
6
Against 2 in 2024 and 4 in 2023
Applications published
51
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry11
Pharmaceuticals8
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Crinetics Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
50 published
CRINETICS PHARMACEUTICALS, INC. its own name
US, as the owner printed on each patent
31 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,492,181Gem-disubstituted piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofOrganic fine chemistryCRINETICS PHARMACEUTICALS, INC.
Nov 25, 202512,479,828Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofOrganic fine chemistryCRINETICS PHARMACEUTICALS, INC.
Nov 25, 202512,479,825Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofOrganic fine chemistryCRINETICS PHARMACEUTICALS, INC.
Nov 11, 202512,466,829Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereofOrganic fine chemistryCRINETICS PHARMACEUTICALS, INC.
Apr 22, 202512,280,046Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of diseasePharmaceuticalsCRINETICS PHARMACEUTICALS, INC.
Jan 28, 202512,208,092Compositions and methods for administering paltusotine to patients with hepatic impairmentPharmaceuticalsCRINETICS PHARMACEUTICALS, INC.
Nov 5, 202412,134,610Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereofBiotechnologyCRINETICS PHARMACEUTICALS, INC.
Apr 16, 202411,957,674Formulations of a somatostatin modulatorPharmaceuticalsCRINETICS PHARMACEUTICALS, INC.
Dec 5, 202311,834,462Somatostatin modulators and uses thereofPharmaceuticalsCRINETICS PHARMACEUTICALS, INC.
Oct 3, 202311,773,076Crystalline forms of a somatostatin modulatorOrganic fine chemistryCRINETICS PHARMACEUTICALS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0367190MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONIST FOR THE TREATMENT OF DISEASEPharmaceuticalsCrinetics Pharmaceuticals, Inc.
Oct 9, 20252025/0312331COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTPharmaceuticalsCrinetics Pharmaceuticals, Inc.
Jul 17, 20252025/0228842USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROMEPharmaceuticalsCrinetics Pharmaceuticals, Inc.
May 1, 20252025/0136573NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOFOrganic fine chemistryCrinetics Pharmaceuticals, Inc.
Dec 12, 20242024/0408247NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOFPharmaceuticalsCrinetics Pharmaceuticals, Inc.
Dec 5, 20242024/0398782FORMULATIONS OF A SOMATOSTATIN MODULATORPharmaceuticalsCrinetics Pharmaceuticals, Inc.
Nov 14, 20242024/0376067PROCESS OF MAKING SOMATOSTATIN MODULATORSOrganic fine chemistryCrinetics Pharmaceuticals, Inc.
Nov 7, 20242024/0366587USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASEPharmaceuticalsCrinetics Pharmaceuticals, Inc.
Oct 3, 20242024/0325376COMPOSITIONS AND METHODS FOR ADMINISTERING PALTUSOTINE TO PATIENTS WITH HEPATIC IMPAIRMENTPharmaceuticalsCrinetics Pharmaceuticals, Inc. · patent 12,208,092 granted from it
Sep 12, 20242024/0300920MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOFOrganic fine chemistryCrinetics Pharmaceuticals, Inc. · patent 12,479,828 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Organic fine chemistry 5 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CRNX · research, not advice